Silverarc Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Silverarc Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,002	Closed	-$2.54M	–	76
2022 Q1	$2.54M	Sell	41,002 -87,899	-68%	-$5.38M	1.05%	24
2021 Q4	$7.11M	Buy	+128,901	New	+$6.72M	2.88%	10

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Silverarc Capital Management's LKFT Position: Q2 2022 in Review

Silverarc Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2022, closing a stake of 41,002 shares — an estimated $2.54M sold.

Silverarc Capital Management first reported a position in LKFT in Q4 2021 and held it in 2 quarters. The position peaked at $7.11M in Q4 2021. 81 funds tracked by Wall St. Rank hold LKFT as of Q2 2022.

Silverarc Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2022 after selling out during the quarter.
Silverarc Capital Management sold 41,002 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2022, an estimated $2.54M.
Silverarc Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2021 and held it in 2 quarters.
Silverarc Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $7.11M in Q4 2021.
81 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2022.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.